{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:33:59Z","timestamp":1789475639300,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T00:00:00Z","timestamp":1329955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-230x-12-18","type":"journal-article","created":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T14:14:14Z","timestamp":1330006454000},"source":"Crossref","is-referenced-by-count":41,"title":["Gaviscon\u00ae vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial"],"prefix":"10.1186","volume":"12","author":[{"given":"Denis","family":"Pouchain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Andr\u00e9","family":"Bigard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Liard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Decaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"McVey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,23]]},"reference":[{"issue":"Suppl 1","key":"695_CR1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000200911","volume":"51","author":"SJ Spechler","year":"1992","unstructured":"Spechler SJ: Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion. 1992, 51 (Suppl 1): 24-29.","journal-title":"Digestion"},{"key":"695_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0755-4982(06)74515-8","volume":"35","author":"JF Bretagne","year":"2006","unstructured":"Bretagne JF, Richard-Molard B, et al: Gastroesophageal reflux in the French general population: national survey of 8000 adults. Presse Med. 2006, 35: 23-31. 10.1016\/S0755-4982(06)74515-8.","journal-title":"Presse Med"},{"key":"695_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002095.pub4","volume-title":"Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease","author":"B van Pinxteren","year":"2010","unstructured":"van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME: Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database of Systematic Reviews. 2010, Art. No.: CD002095. DOI: 10.1002\/14651858.CD002095.pub4, 11"},{"key":"695_CR4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1542-3565(04)00288-5","volume":"2","author":"BB Dean","year":"2004","unstructured":"Dean BB, Gano AD, Knight K, et al: Effectiveness of proton pump inhibitors in non-erosive reflux disease. Clin Gastroenterol Hepatol. 2004, 2: 656-664. 10.1016\/S1542-3565(04)00288-5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"695_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0140-6736(74)92340-X","volume":"1","author":"C Stanciu","year":"1974","unstructured":"Stanciu C, Bennett JR: Alginate-antacid in the reduction of gastro-oesophageal reflux. Lancet. 1974, 1: 109-111.","journal-title":"Lancet"},{"key":"695_CR6","first-page":"984","volume":"15","author":"B Filoche","year":"1991","unstructured":"Filoche B, Carteret E, Couzigou B, et al: Randomized double-blind trial with a liquid suspension of alginate for the treatment of pyrosis. Gastroenterol Clin Biol. 1991, 15: 984-985.","journal-title":"Gastroenterol Clin Biol"},{"key":"695_CR7","first-page":"423","volume":"74","author":"AE Grossmann","year":"1973","unstructured":"Grossmann AE, Klotz AP, Rhodes JB, Korb T: Reflux oesophagitis. A comparison of old and new medical management. J Kans Med Soc. 1973, 74: 423-424.","journal-title":"J Kans Med Soc"},{"key":"695_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1185\/03007997509114793","volume":"3","author":"DE Barnardo","year":"1975","unstructured":"Barnardo DE, Lancaster-Smith M, Strickland ID, Wright JT: A double-blind controlled trial of \"Gaviscon\" in patients with symptomatic gastro-oesophageal reflux. Curr Med Res Opin. 1975, 3: 388-391. 10.1185\/03007997509114793.","journal-title":"Curr Med Res Opin"},{"key":"695_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007997209111146","volume":"1","author":"M Beeley","year":"1972","unstructured":"Beeley M, Warner JO: Medical treatment of symptomatic hiatus hernia with low-density compounds. Curr Med Res Opin. 1972, 1: 63-69. 10.1185\/03007997209111146.","journal-title":"Curr Med Res Opin"},{"key":"695_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1185\/03007999909114086","volume":"15","author":"S Chatfield","year":"1999","unstructured":"Chatfield S: A Comparison of the efficacy of the alginate preparation, Gaviscon advance, with placebo in the treatment of gastro-oesophageal reflux disease. Curr Med Res Opin. 1999, 15: 152-159. 10.1185\/03007999909114086.","journal-title":"Curr Med Res Opin"},{"key":"695_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijpharm.2005.01.036","volume":"294","author":"FC Hampson","year":"2005","unstructured":"Hampson FC, Farndale A, Strugala V, et al: Alginate rafts and their characterisation. Int J Pharm. 2005, 294: 137-147. 10.1016\/j.ijpharm.2005.01.036.","journal-title":"Int J Pharm"},{"key":"695_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/sim.1425","volume":"22","author":"RB D'Agostino","year":"2003","unstructured":"D'Agostino RB, Massaro JM, Sullivan LM: Non-inferiority trials: design, concepts and issues - the encounters of academic consultants in statistics. Statist Med. 2003, 22: 169-186.","journal-title":"Statist Med"},{"key":"695_CR13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/j.1572-0241.2002.05769.x","volume":"97","author":"P Miner Jr","year":"2002","unstructured":"Miner P, Orr W, Filippone J, et al: Rabeprazole in non-erosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002, 97: 1332-1339. 10.1111\/j.1572-0241.2002.05769.x.","journal-title":"Am J Gastroenterol"},{"key":"695_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000085576","volume":"71","author":"H Monnikes","year":"2005","unstructured":"Monnikes H, Pfaffenberger B, Gatz G, et al: Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion. 2005, 71: 152-158. 10.1159\/000085576.","journal-title":"Digestion"},{"key":"695_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","volume":"10","author":"JM Shin","year":"2008","unstructured":"Shin JM, Sachs G: Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008, 10: 528-534. 10.1007\/s11894-008-0098-4.","journal-title":"Curr Gastroenterol Rep"},{"key":"695_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/BF01307584","volume":"37","author":"DO Castell","year":"1992","unstructured":"Castell DO, Dalton CB, Becker D, et al: Alginic acid decreases postprandial upright gastroesophageal reflux. Comparison with equal-strength antacid. Dig Dis Sci. 1992, 37: 589-593. 10.1007\/BF01307584.","journal-title":"Dig Dis Sci"},{"key":"695_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1365-2036.1990.tb00509.x","volume":"4","author":"JR Lambert","year":"1990","unstructured":"Lambert JR, Korman MG, Nicholson L, Chan JG: In-vivo anti-reflux and raft properties of alginates. Aliment Pharmacol Ther. 1990, 4: 615-622.","journal-title":"Aliment Pharmacol Ther"},{"key":"695_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1046\/j.1365-2036.2000.00759.x","volume":"14","author":"KG Mandel","year":"2000","unstructured":"Mandel KG, Daggy BP, Brodie DA, Jacoby HI: Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000, 14: 669-690. 10.1046\/j.1365-2036.2000.00759.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"695_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2036.2004.02085.x","volume":"20","author":"D Armstrong","year":"2004","unstructured":"Armstrong D, Talley NJ, Lauritsen K, et al: The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004, 20: 413-421. 10.1111\/j.1365-2036.2004.02085.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"695_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0016-5085(92)91790-B","volume":"102","author":"SJ Sontag","year":"1992","unstructured":"Sontag SJ, Hirschowitz BI, Holt S, et al: Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology. 1992, 102: 109-118.","journal-title":"Gastroenterology"},{"key":"695_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2036.2011.04678.x","volume":"34","author":"MA Kwiatec","year":"2011","unstructured":"Kwiatec MA, Roman SA, Fareeduddin A: An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial \"acid pocket\" in symptomatic GERD patients. Aliment Pharmacol Ther. 2011, 34: 59-66. 10.1111\/j.1365-2036.2011.04678.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"695_CR22","doi-asserted-by":"crossref","unstructured":"An evidence-based appraisal of reflux disease management--the Genval Workshop Report. Gut. 1999, 44 (suppl 1): 1-16.","DOI":"10.1136\/gut.44.2008.S1"},{"key":"695_CR23","unstructured":"Gastroesophageal reflux in adults: diagnosis and treatment. Conclusions of Consensus Conference: long text. Organized by the French National Society of Gastroenterology and Belgian Royal Society of Gastroenterology\/Flemish Society of Gastroenterology. French Society of Digestive Surgery. French Society of Digestive Endoscopy. French Society of Pharmacology. Gastroenterol Clin Biol. 1999, 23: 56-65."},{"key":"695_CR24","first-page":"47","volume-title":"Clinical Guideline 17","author":"New Castle Guideline Development and Research Unit. Dyspepsia","year":"2004","unstructured":"New Castle Guideline Development and Research Unit. Dyspepsia: Management of dyspepsia in adults in primary care. National Institute for Clinical Excellence. Clinical Guideline 17. 2004, 47-Available at: \n                    http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG017NICEguideline.pdf\n                    \n                  . Last access: 24 August 2011"},{"key":"695_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1440-1746.2004.03419.x","volume":"19","author":"KM Fock","year":"2004","unstructured":"Fock KM, Talley N, Hunt R, et al: Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2004, 19: 357-367. 10.1111\/j.1440-1746.2004.03419.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"695_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","volume":"100","author":"KR DeVault","year":"2005","unstructured":"DeVault KR, Castell DO: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005, 100: 190-200. 10.1111\/j.1572-0241.2005.41217.x.","journal-title":"Am J Gastroenterol"},{"key":"695_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1155\/2005\/836030","volume":"19","author":"D Armstrong","year":"2005","unstructured":"Armstrong D, Marshall JK, Chiba N, et al: Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol. 2005, 19: 15-35.","journal-title":"Can J Gastroenterol"},{"key":"695_CR28","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2008.08.045","volume":"135","author":"PJ Kahrilas","year":"2008","unstructured":"Kahrilas PJ, Shaheen NJ, Vaezi MF, et al: American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008, 135: 1383-1391, 1391 e1-5. 10.1053\/j.gastro.2008.08.045.","journal-title":"Gastroenterology"},{"key":"695_CR29","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/j.1365-2036.2005.02490.x","volume":"21","author":"J Zacny","year":"2005","unstructured":"Zacny J, Zamakhshary M, Sketris I, et al: Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther. 2005, 21: 1299-1312. 10.1111\/j.1365-2036.2005.02490.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"695_CR30","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00228-010-0871-9","volume":"66","author":"D Ahrens","year":"2010","unstructured":"Ahrens D, Chenot JF, Behrens G, et al: Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010, 66: 1265-1271. 10.1007\/s00228-010-0871-9.","journal-title":"Eur J Clin Pharmacol"},{"key":"695_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jama.2009.261","volume":"301","author":"PM Ho","year":"2009","unstructured":"Ho PM, Maddox TM, Wang L, et al: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009, 301: 937-944. 10.1001\/jama.2009.261.","journal-title":"JAMA"},{"key":"695_CR32","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Cryer BL, Contant CF, et al: Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010, 363: 1909-1917. 10.1056\/NEJMoa1007964.","journal-title":"N Engl J Med"},{"key":"695_CR33","first-page":"363","volume":"2010","author":"MR Southworth","year":"1977","unstructured":"Southworth MR, Temple R: Interaction of clopidogrel and omeprazole. N Engl J Med. 1977, 2010: 363-","journal-title":"N Engl J Med"},{"key":"695_CR34","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1001\/jama.294.23.2989","volume":"294","author":"S Dial","year":"2005","unstructured":"Dial S, Delaney JA, Barkun AN, Suissa S: Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005, 294: 2989-2995. 10.1001\/jama.294.23.2989.","journal-title":"JAMA"},{"key":"695_CR35","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","volume":"292","author":"RJ Laheij","year":"2004","unstructured":"Laheij RJ, Sturkenboom MC, Hassing RJ, et al: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004, 292: 1955-1960. 10.1001\/jama.292.16.1955.","journal-title":"JAMA"},{"key":"695_CR36","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"YX Yang","year":"2006","unstructured":"Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006, 296: 2947-2953. 10.1001\/jama.296.24.2947.","journal-title":"JAMA"},{"key":"695_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1053\/j.gastro.2010.03.055","volume":"139","author":"DA Corley","year":"2010","unstructured":"Corley DA, Kubo A, Zhao W, Quesenberry C: Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010, 139: 93-101. 10.1053\/j.gastro.2010.03.055.","journal-title":"Gastroenterology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-230X-12-18\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-12-18.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-12-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-12-18.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T03:28:11Z","timestamp":1548127691000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/1471-230X-12-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,23]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1186\/1471-230x-12-18","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,23]]},"article-number":"18"}}